PROM1 and colorectal carcinoma: CRC CSCs are also able to survive following therapeutic interventions; CD133+ CRC CSCs have been demonstrated as more resistant to 5-fluorouracil, with higher invasiveness and metastatic potential compared to CD133- CRC CSCs [45,92].